Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of tick-borne encephalitis vaccine in healthy Japanese participants aged 1 year and older
jRCT2031200302Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (2 arms), sponsored by Pfizer. Primary endpoints: Seropositivity rate in participants ≥16 years 4 weeks after Dose 3, Seropositivity rate in participants 1 to <16 years 4 weeks after Dose 3 and 4 more. Started Jan 2021; status: completed.
02
Drugs
Tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on jRCT2031200302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200302.